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Abstract
Background: Spinocerebellar ataxia type 2 (SCA2) affects several neurological structures, giving rise to multiple
symptoms. However, only the natural history of ataxia is well known, as measured during the study duration. We
aimed to describe the progression rate of ataxia, by the Scale for the Assessment and Rating of Ataxia (SARA), as
well as the progression rate of the overall neurological picture, by the Neurological Examination Score for
Spinocerebellar Ataxias (NESSCA), and not only during the study duration but also in a disease duration model.
Comparisons between these models might allow us to explore whether progression is linear during the disease
duration in SCA2; and to look for potential modifiers.
Results: Eighty–eight evaluations were prospectively done on 49 symptomatic subjects; on average (SD), study
duration and disease duration models covered 13 (2.16) months and 14 (6.66) years of individuals’ life, respectively.
SARA progressed 1.75 (CI 95%: 0.92–2.57) versus 0.79 (95% CI 0.45 to 1.14) points/year in the study duration and
disease duration models. NESSCA progressed 1.45 (CI 95%: 0.74–2.16) versus 0.41 (95% CI 0.24 to 0.59) points/year in
the same models. In order to explain these discrepancies, the progression rates of the study duration model were
plotted against disease duration. Then an acceleration was detected after 10 years of disease duration: SARA scores
progressed 0.35 before and 2.45 points/year after this deadline (p = 0.013). Age at onset, mutation severity, and
presence of amyotrophy, parkinsonism, dystonic manifestations and cognitive decline at baseline did not influence
the rate of disease progression.
Conclusions: NESSCA and SARA progression rates were not constant during disease duration in SCA2: early phases
of disease were associated with slower progressions. Modelling of future clinical trials on SCA2 should take this
phenomenon into account, since disease duration might impact on inclusion criteria, sample size, and study duration.
Our database is available online and accessible to future studies aimed to compare the present data with other cohorts.
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Background
The spinocerebellar ataxia type 2 (SCA2) is one of the
most common polyglutamine (polyQ) disorders. Caused
by a dominant expansion of a CAG repeat tract
(CAGexp) at ATXN2, SCA2 is related to a polyQ with
more than 32–33 glutamines in ataxin-2 [1]. Disease
usually starts in adulthood and clinical picture is not
homogeneous. Main symptoms are related to cerebellar
dysfunction, and include ataxic gait, cerebellar dysarthria
as well as dysmetria [2]. Severe saccade slowing and per-
ipheral neuropathy are very frequent and affect more
than 50% of case series [3]. Besides, several other mani-
festations might appear, such as pyramidal findings,
extrapyramidal syndromes (including dystonic move-
ments and parkinsonism), lower motor neuron findings,
cognitive deterioration, and others [4–6]. ATXN2 expan-
sion explains most but not all variability in age at onset
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(AO) of symptoms [1], and it was related to presence of
some neurological findings such as dystonic movements
and parkinsonism [7]. Mean (SD) age at onset was
around 30 to 33 (14) years [8, 9] and median survival
was 68 [95% CI: 65–70] years, usually after a wheelchair
period [10].
Description of disease progression in SCA2 depends
on a comprehensive disease-progression model as well
as in other SCAs. Several challenges hamper this, such
as heterogeneous subphenotypes evolving in time, rarity,
and the long duration of disease. Moreover, effects re-
lated to genetic or environmental background cannot be
discarded. Clinical scales appropriated to the phenotype,
description of disease progression in more than one co-
hort, and anticipating potential drawbacks from data ob-
tained from short duration clinical studies are some of
the questions investigators should keep in mind [11].
As stated before, SCA2 symptoms are very heteroge-
neous. In spite of that, majority of longitudinal studies
followed ataxic manifestations only, as measured by Scale
for the Assessment and Rating of Ataxia (SARA) [12],
SCA Functional-Index (SCAFI) [13], and Composite-
Cerebellar-Functional-Score (CCFS) [14]. The natural his-
tory (NH) of SARA has been measured a couple of times
in SCA2 patients [15–19]. NH of SCAFI and CCFS were
described only once for each, with insufficient or non-
significant progression rates [18, 20]. An unique study
followed up extra-cerebellar findings by using the inven-
tory of non-ataxic symptoms (INAS); however, non satis-
factory results were raised [15, 16].
Most longitudinal observations of neurological scales in
SCAs used the study entry as the time correspondent to
the start of the measurements. First measurements were
considered as baseline, abscissa axis was the chronological
time since the beginning of study, and the slope of pro-
gression was obtained by comparing these data with those
obtained at latter observations, usually at fixed intervals
[15, 16, 18, 19]. Other studies chose to add age at onset in-
formed by the individual into the model: in these studies,
the abscissa axis presented the whole disease duration [21,
22]. If the actual progression rate of the disease is continu-
ous and linear, the slopes obtained by both models should
be similar. In contrast, if slopes obtained with these two
models are different, this means that progression is not
linear and must be further explored.
Our aims were to describe the progression rate of
neurological manifestations in a new SCA2 cohort, as
measured by the ataxia scales SARA, SCAFI, and
CCFS, and by a comprehensive neurologic scale, the
Neurological Examination Score for Spinocerebellar
Ataxias (NESSCA) [23, 24]; to explore if progression
rates are linear during the whole disease duration
since onset of gait ataxia; and to look for potential
modifiers of disease progression.
Methods
Symptomatic carriers with a molecular diagnosis of
SCA2, under care in outpatient clinics of University
hospitals of Porto Alegre, Rio de Janeiro, and São Paulo,
Brazil, were invited to participate in this study.
Investigators trained in the scales (TLM, ERR, MA,
ASPS) applied NESSCA, SARA, SCAFI, CCFS, and
mini-mental state examination (MMSE) in the partici-
pants at baseline and in a second visit planned to occur
12 months later. Data was registered in protected files.
Independent variables under study were the following:
age, gender, age at onset of gait ataxia (AOga), age at on-
set of first symptom (AOfs), disease duration since start
of gait ataxia (DDga), disease duration since start of first
symptom (DDfs), and the number of CAG repeats in
both alleles. Molecular studies were performed as
previously described [6]. Phenotypic subgroups were
built according to presence or absence of amyotrophy,
parkinsonism, dystonia, and cognitive losses, as previ-
ously described [7]. They were used as additional inde-
pendent variables. Briefly, amyotrophy was considered
present if fasciculations in regions other than face, or
muscle tissue loss were found (items 8 and 15 of
NESSCA) [22 23]. Parkinsonism was present if at least
two out of three manifestations were documented - bra-
dykinesia, rigidity, and resting tremor (items 11 and 12
of NESSCA) [23, 25]. Dystonia was considered present if
dystonic movements impaired in some degree the volun-
tary movements (at least 2 points on item 10 of
NESSCA) [23]. Cognitive decline was considered present
according to Folstein criteria for MMSE [26].
Modeling
Linear growth curve models, i.e., mixed models with in-
tercepts and random slopes, were adjusted to model the
relationship between outcomes and time. The annual
rate of increase was estimated in two different ways:
– Study duration model: A mean change per studied
year. Points in time included in this model were the
study entry (first observation was the baseline), and
12 and 24 months later (follow up observations).
– Disease duration model: A mean change since the
disease onset, according to patient’s report. In this
model, at least three time points were of interest:
the time of onset of gait ataxia (baseline), the study
entry (first observation), and 12 and 24 months later
(follow up observations). The progression rate was
that estimated to occur during all disease duration.
These different strategies followed the recommenda-
tion of Singer and Willett (2003) [27] of investigating
alternative temporal specifications. The progression rate
obtained during the study duration model was defined
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as the standard model in the present analysis. If lopes
derived from both models were different, the raised hy-
pothesis was that the progression is highly dependent on
disease duration, and then a binary variable would be in-
cluded in the study duration model, according to the ap-
parent effect of disease duration on shifting the
progression rate.
A variance component covariance matrix was used for
the intercepts and random slopes. Models were fitted in
R 3.2.2 software, using lme4 package. P-values were ob-
tained through likelihood ratio tests, using Anova func-
tion of car package. Bootstrap replicates were used to
produce confidence intervals for the fitted curves.
Ethics approval and consent to participate
The study protocol was approved by the institutional
ethical standards committees on human experimentation
of all contributing centers (registered as 12–0346 at
Comissao de Etica em Pesquisa of our institution, and as
07105712.1.0000.5327 at the Brazilian National platform,
Plataforma Brasil). All patients gave written informed
consent to participate in the study.
Consent for publication
Not applicable – this report does not contain any indi-
vidual persons data.
Results
Forty-nine SCA2 symptomatic carriers (27 men) were
included in the baseline analysis, and thirty-eight follow-
up evaluations were done. Clinical and molecular char-
acteristics at baseline were already described [7]. Table 1
summarizes demographic data, genetic and neurological
findings at baseline (all similar between genders). The
original database was anonymized and is also available
for readers (Additional file 1).
Progression rates
Progression rates were obtained for SARA, NESSCA,
CCFS and SCAFI according to the mean change per
studied year (study duration model) and to mean change
since the disease onset (disease duration model).
SARA progressed 1.75 points/year (95% CI: 0.92–2.57)
in the study duration model and only 0.79 points/year
(95% CI 0.45 to 1.14) in the disease duration model.
NESSCA progressed 1.45 points/year (CI 95%: 0.74–
2.16) in the study duration model and only 0.41 points/
year (95% CI 0.24 to 0.59) in the disease duration model.
SCAFI progressed just −0.05 points/year (95% -0.09 to
−0.01) in the disease duration model. SCAFI did not
present a significant progression in the study duration
model, while CCFS did not present significant progres-
sions in both models.
The above results documented that there were differ-
ences in the progression rates of SARA and NESSCA
when both models were applied. The hypothesis was
that the progression rate of these scales was not constant
during disease duration. Deltas of SARA and NESSCA
observed in one year (the study duration model) were
then plotted against disease duration in order to deter-
mine a cutoff value for the subsequent stratification of
the study duration analysis.
Sixteen out of 38 subjects evaluated in the follow-up
had 10 or less years of DD. Figure 1A shows that 2/16
subjects with less than 10 years of disease duration pro-
gressed 3 points – and none of them progressed more
Table 1 - Demographic, molecular and neurologic features of
study population at baseline
N subjects (M/F) 49 (27/22)
Age at first examination (years) 46.35 ± 12.26
(24 to 71)a
Age at onset of gait ataxia (years) 33.23 ± 12.37
(12 to 59)a
Number of CAG repeats at normal ATXN2 22.26 ± 0.80
(22 to 27)a
Number of CAG repeats at expanded ATXN2 40.35 ± 3.21
(34 to 49)a
Disease duration at study entry (years) 12.94 ± 6.66
(2 to 27)a
NESSCA at baseline 14.37 ± 4.32
(3 to 27)a
SARA at baseline 18.42 ± 8.17
(5 to 33)a
Main neurological findings at baseline:
Gait ataxia 49/49
Sensory losses (at least two altered proofs
on lower limbs - pin prick/light touch,
hot/cold (discrimination) and vibration
sensations
19/43b
Pyramidal syndrome (at least two of the




Fasciculations and amyotrophy 7/49
Dystonia (dystonic movements that impair
in some degree voluntary movements)
8/49
Parkinsonism (at least two of the following:
rigidity, bradychinesia, rest tremor)
17/49
With cognitive decline (MMSE c < = 24 or




Without cognitive decline 37/49
25.9 ± 2.9
(19 to 30)a
a mean and standard deviation (range)
b Six subjects were excluded due to the presence of comorbidities such as
diabetes melittus
c MMSE: Mini Mental State Evatuation
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than that -, whereas 10/22 individuals with more than
10 years of disease duration progressed 3 or more points
in SARA scores in one year (chi-square = 4.66, p =
0.031). Age, AO and CAGexp at ATXN2 were similar
between these DD groups and did not influence their
deltaSARAs (data not shown).
Progression rates of SARA were shown in Fig. 2, using
the cutoff of 10 years of disease duration to stratify our
cohort. Symptomatic SCA2 individuals with less and
more than 10 years of disease duration progressed 0.35
and 2.45 points/year in SARA scores (p = 0.013),
respectively.
Figure 1B shows that NESSCA progression is also
lower in the first 10 years of disease duration than later
on. NESSCA progression turned fast after 10 years, and
slowed again after 20 years of disease duration. Due to
this finding, and in order to examine the effect of disease
stage on the slopes, we have studied further NESSCAs
from individuals with less than 20 years of disease dur-
ation only, by using the cutoff of 10 years of disease dur-
ation. Progression rates of NESSCA were shown in
Fig. 3. Symptomatic SCA2 individuals with less and
more than 10 years of disease duration progressed 1.03
and 2.14 points/year in NESSCA scores (p = 0.191),
respectively.
Modifier factors
Gender, AOga, AOfs, CAGexp at ATXN2, and presence/
absence of amyotrophy, parkinsonism, dystonic manifes-
tations and cognitive decline at baseline, were studied as
potential modifier factor of disease progression accord-
ing to both models (study duration model and disease
duration model). None of them produced significant dif-
ferences in the progression rates - even using the disease
duration strata revealed in Figs. 1 ,2, and 3. Figure 4
shows an example of the NESSCA and SARA
Fig. 1 - Differences (deltas) between baseline and follow up observations 12 months later, according to disease duration since onset of gait
ataxia. (a) Deltas of SARA scores were lower than 3 in the first 10 years of disease duration (b) Deltas of NESSCA scores during the first 10 years
and after 20 years of disease duration were also lower than those observed in 10–20 years of disease duration
Fig. 2 - SARA progression during the study duration, according to
disease duration strata
Fig. 3 - NESSCA progression during study duration, according to
disease duration strata
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progression rates obtained in subjects with and without
cognitive decline.
Discussion
Our results showed that progression rates of SARA and
NESSCA were not constant during the long disease dur-
ation of SCA2 symptomatic patients. At early phases,
i.e., in the first 10 years of the disease, progression rates
of both scales were slower than in the following years.
This phenomenon might be due to the psychometric
characteristics of scales or to biological causes. Whatever
the reason, the direct use of linear models during pro-
spective longitudinal observations without paying atten-
tion to differences in disease duration might keep these
non-linear progressions hidden.
At least nine studies followed SCA2 patients with lon-
gitudinal observations [15–19, 28–31]. In most cases
where SARA progression was measured, annual worsen-
ing was around 1.5 to 1.9 points [15, 16, 18, 19, 30]. The
methodology of analysis of two of these former cohorts
were similar to that from our group therefore, our re-
sults can be compared to those studies [15, 16, 18]. Our
observations related to the study duration analysis raised
a SARA progression of 1.75 points/year, which is com-
parable to theirs. However, neither observations related
to disease duration (Fig. 1) nor discrepancy of results ob-
tained by the two models has been reported before.
Disease progression of a cohort of 35 SCA2 patients
living in France was analysed using mixed models with a
random effect for patients and the fixed effects group
and time between inclusion and clinical examination
[18]. Authors found that SARA worsened 1.3 (0.2)
points per year. Factors associated with faster SARA
progression were male gender, and patients who were
younger at onset. Disease duration and CAGexp did not
change SARA progression in that cohort. The Eurosca
study included 163 SCA2 patients from several Euro-
pean countries in a longitudinal cohort, and linearity of
the progression rate was tested via nested models (likeli-
hood ratio test), followed by an analysis of covariance
where the effect of gender, age at onset, disease duration, and
repeat length of the expanded allele were tested [15, 16].
SARA worsened 1.40 points per year. Earlier age at onset
and longer expanded alleles were associated with faster
SARA progression: in the multivariate analysis, age at onset
was the only independent factor. Thirty Cuban symptomatic
subjects were evaluated four times (baseline, and at 1, 2, and
5 years), in a study that longitudinally followed variations in
SARA and in saccades: the exponential progression rate of
the SARA score was associated to the CAGexp [19].
Therefore, previous SCA2 cohorts showed effects of
gender, early ages at onset or of CAGexp on speeding
SARA progression. None detected a difference related to
disease duration. In contrast, our cohort showed a trend
to associate a faster NESSCA (not SARA) progression to
larger CAGexp. These discrepancies can be due to dif-
ferences in sample sizes - the number of observations
impacting on the choice of statistical modeling -, or to
truly differences between cohorts with diverse popula-
tional origins.
Contrary to previous cohorts, our longitudinal obser-
vation was able to pick up a clear effect of disease dur-
ation on the slope of progression of SARA and
NESSCA. This effect was detected because of the dis-
crepancy between the slopes obtained with the two
models: the study duration and the disease duration
Fig. 4 - Disease progression as measured by clinical scales in SCA2 individuals according to disease duration model. (a) NESSCA progression.
(b) SARA progression. Hatched lines describe progression rates of subjects with cognitive decline, while continuous lines describe progression
rates of subjects without cognitive decline
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models. Discrepancy led us to look for deltas distribu-
tions (Fig. 1) and a cutoff value was chosen with the em-
pirical data. Both Jacobi et al. [15] and Tezenas du
Montcel et al. [18] analysed the data by the study dur-
ation, using the time between inclusion and clinical
examination as one of the fixed effects. We questioned
whether the treatment of disease duration in their model
was unable to reveal this variable as a modifier. It is rele-
vant to state that disease duration entered their model
as a factor whose interaction with progression rate was
tested with a mathematical treatment - either as a con-
tinuous or a dichotomous variable, splitted by the me-
dian. This procedure fitted totally with the generalized
linear mixed model; but it might be insufficient to clarify
the problem. A good way to shed light into this problem
will be to perform either multicentric studies or a meta-
analysis. Our database is available online with the
present communication in order to help any of these
approaches.
Non linear are as plausible as linear progressions for
neurodegenerative diseases and were already clearly pro-
posed for SCA2 [19]. In Huntington disease (HD), an-
other polyQ disorder, progression rates of chorea and of
caudate atrophy are not linear. Slopes for caudate atro-
phy changes with the clinical stage [32]. The annual rate
of increase in chorea is greater among individuals with
earlier-stage HD than in those with advanced HD [33].
Reasons for non-linearity might include scale limitations
and truly natural phenomena. For instance, NESSCA
progression seemed to be slower either in the first as
well as in the last years of the disease (Fig. 1B). We pos-
tulate that the slowdown seen after 20 years of the dis-
ease more probably reflects the inability of this scale to
measure progression after a certain disease stage. In any
case, statistical modeling is an issue for discontinuous
deteriorations. In another study, we used markov chains
to describe the progression of several neurological find-
ings in SCA3/Machado Joseph disease (SCA3/MJD). Al-
though markov chains are quite uneasy and unfamiliar
for clinical researchers, this model disclosed that isolated
findings, such as gait ataxia, limb ataxia, dystonic mani-
festations and others, followed a curvilinear trajectory as
the disease progressed [21]. Perhaps the present ap-
proach, where the use of mixed models was done in two
stracta, splitted by a cutoff for dichotomous (dummy)
observations chosen by an immediate, empirical data
judged by eye inspection, can be more helpful.
Conclusions
The present study suggested that the speed of progres-
sion of scales SARA and NESSCA is not uniform during
the disease process in SCA2, varying according to stage
of disease. General progression rates of SARA and
NESSCA were either similar to others studies in SCA2
(1.7 points per year in the case of SARA) or very like
other SCA (1.45 points per year in the case of NESSCA,
similar to the progression found in SCA3/MJD), while
general progression of SCAFI and CCFS were non sig-
nificant, at least in the study duration model. Early
phases of disease were associated with slower SARA and
NESSCA progressions, when compared to phases after
10 years of disease onset. Future clinical trials on SCA2
should take this into account when estimating sample
size/study duration. Moreover, we recommend that dis-
ease duration should be included in recruitment criteria.
Finally, our database is available online and accessible to
future studies aimed to compare our cohort with other
databases. A meta-analysis would be the best way to elu-
cidate all events that influence the progression of this
disease.
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